It is hard to understand why head way is not being made wrt a Chinese Covid trial. Previously I have read that the ownership of HL is very well connected politically as well as financially, not to mention ORIStars connections.

It is also hard to understand why the Canadian/Brazilian Covid trial has not made more progress. The preliminary science is arguably outstanding and Norman Wong is a very well respected, well published clinician/researcher. One would think he might have some influence in spurring this process forward (Clinicaltrials.gov has not been updated by the company since January so perhaps part of our view of the trial is obscured by poor corporate administration).  

Additionally, I just saw on the news today that Ontario is now bracing for a 6th Covid wave.  Brazil seems far from out of the woods. The US is also far from out of the woods and their amount of increased and planned expenditure to combat Covid is staggering.  One would think that an organized, respected management team with the kind of science inherent to RVX would be able to reach the right people in government to assist in expediting the ph2 in Canada and Brazil and the US ph3. The impact of a successful trial on the global community would obviously be enormous, the downside risk is negligible.  Hard to understand RVX delays/ineffectiveness.

If RVX was a well run, well funded company it would be hard to believe that this "small inexpensive trial" (ph2) would not be complete by now. Over 2 years and counting since Don first started "announcing" the trial. Give us a break!  Get down to business!